# Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study

> **NCT06037239** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 53 (estimated)

## Conditions studied

- Cutaneous T-cell Lymphoma

## Interventions

- **DRUG:** Linperlisib in combined with Chidamide

## Key facts

- **NCT ID:** NCT06037239
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-01
- **Primary completion:** 2024-07
- **Final completion:** 2025-07
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2023-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06037239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06037239, "Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06037239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*